CN100471838C - Vla-4抑制剂 - Google Patents

Vla-4抑制剂 Download PDF

Info

Publication number
CN100471838C
CN100471838C CNB018214843A CN01821484A CN100471838C CN 100471838 C CN100471838 C CN 100471838C CN B018214843 A CNB018214843 A CN B018214843A CN 01821484 A CN01821484 A CN 01821484A CN 100471838 C CN100471838 C CN 100471838C
Authority
CN
China
Prior art keywords
group
compound
expression
fluoro
methoxyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018214843A
Other languages
English (en)
Chinese (zh)
Other versions
CN1483024A (zh
Inventor
中山敦
町永信雄
米田贺行
杉本雄一
千叶淳
渡边俊之
饭村信
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Publication of CN1483024A publication Critical patent/CN1483024A/zh
Application granted granted Critical
Publication of CN100471838C publication Critical patent/CN100471838C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB018214843A 2000-12-28 2001-12-28 Vla-4抑制剂 Expired - Fee Related CN100471838C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP402890/2000 2000-12-28
JP2000402890 2000-12-28
JP402890/00 2000-12-28
JP149923/2001 2001-05-18
JP2001149923 2001-05-18
JP149923/01 2001-05-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100737061A Division CN100396680C (zh) 2000-12-28 2001-12-28 极迟抗原-4抑制剂

Publications (2)

Publication Number Publication Date
CN1483024A CN1483024A (zh) 2004-03-17
CN100471838C true CN100471838C (zh) 2009-03-25

Family

ID=26607210

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018214843A Expired - Fee Related CN100471838C (zh) 2000-12-28 2001-12-28 Vla-4抑制剂

Country Status (16)

Country Link
US (1) US7157487B2 (enExample)
EP (1) EP1346982B1 (enExample)
JP (1) JP4212358B2 (enExample)
KR (1) KR100884877B1 (enExample)
CN (1) CN100471838C (enExample)
AR (1) AR035218A1 (enExample)
AT (1) ATE524441T1 (enExample)
AU (1) AU2002219555B2 (enExample)
BR (1) BR0116608A (enExample)
CA (1) CA2430978C (enExample)
IL (1) IL156064A0 (enExample)
MX (1) MXPA03005838A (enExample)
NO (1) NO326014B1 (enExample)
RU (1) RU2290403C2 (enExample)
TW (1) TWI312779B (enExample)
WO (1) WO2002053534A1 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
EA007987B1 (ru) * 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
PL375149A1 (en) * 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
WO2004099136A1 (ja) * 2003-05-09 2004-11-18 Daiichi Pharmaceutical Co., Ltd. ピロリジン誘導体の製造方法
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
ES2382806T3 (es) 2003-07-24 2012-06-13 Daiichi Sankyo Company, Limited Compuesto ácido ciclohexanocarboxílico
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
EP1698611A4 (en) * 2003-12-26 2007-10-31 Daiichi Seiyaku Co PROCESS FOR PRODUCING A PHENYLACETIC ACID DERIVATIVE
EP1698621A4 (en) * 2003-12-26 2008-11-19 Daiichi Seiyaku Co PROCESS FOR PREPARING A PYRROLIDINE DERIVATIVE
WO2005090329A1 (en) * 2004-03-24 2005-09-29 Jerini Ag New compounds for the inhibition of angiogenesis and use of thereof
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
TW200610754A (en) * 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体
EP1831225A2 (en) * 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
WO2007023882A1 (ja) * 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Ｐｐａｒアゴニスト活性を有する誘導体
EP1961750B1 (en) * 2005-12-13 2013-09-18 Daiichi Sankyo Company, Limited Vla-4 inhibitory drug
KR20090017498A (ko) 2006-04-04 2009-02-18 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Ｐｉ３ 키나제 길항물질
DE102006021878A1 (de) * 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7858645B2 (en) * 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) * 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
DK2358720T3 (en) 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
PL2376485T3 (pl) 2008-12-19 2018-05-30 Vertex Pharmaceuticals Incorporated Pochodne pirazyny użyteczne jako inhibitory kinazy ATR
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
JP2012529517A (ja) 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ベンジル置換トリアジン誘導体類及びそれらの治療応用
KR101457027B1 (ko) 2009-06-09 2014-10-31 캘리포니아 캐피탈 에쿼티, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
CA2765053C (en) 2009-06-09 2015-08-18 California Capital Equity, Llc Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR20150061651A (ko) 2012-09-26 2015-06-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ire1의 조절
CA2890105C (en) 2012-11-01 2023-03-21 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016071499A1 (en) * 2014-11-06 2016-05-12 Basf Se 3-pyridyl heterobicyclic compound for controlling invertebrate pests
RU2715897C2 (ru) 2015-06-09 2020-03-04 Эббви Инк. Модуляторы ядерных рецепторов
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
US20220119383A1 (en) 2018-10-30 2022-04-21 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN119431230A (zh) 2019-08-14 2025-02-14 吉利德科学公司 用于抑制α4β7整合素的化合物
PH12022553378A1 (en) 2020-06-10 2024-03-25 Univ Leuven Kath Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
EP4366831A4 (en) 2021-07-09 2025-06-11 Aligos Therapeutics, Inc. ANTI-VIRAL COMPOUNDS
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181658A (en) * 1977-02-18 1980-01-01 Hoechst Aktiengesellschaft Certain nicotinamido-n-benzoic acid derivatives
US4221815A (en) * 1975-01-03 1980-09-09 Hoechst Aktiengesellschaft Benzoic acids, their derivatives and process for preparing them
EP0023569A1 (de) * 1979-07-13 1981-02-11 Dr. Karl Thomae GmbH Carbonsäure-Derivate, deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0585155A1 (fr) * 1992-07-28 1994-03-02 Adir Et Compagnie Peptides dérivés de trifluorométhylcétones ayant une actovoté inhibants d'élastase leucocytaire humaine (HLE), leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO1995030673A1 (en) * 1994-05-05 1995-11-16 British Technology Group Limited Anti-cancer compounds containing cyclopentaquinazoline ring
WO1996004267A1 (en) * 1994-08-01 1996-02-15 Laboratorios Menarini S.A. Naphthalene amides having leukotriene-antagonistic action
WO1997002024A1 (en) * 1995-06-30 1997-01-23 Smithkline Beecham Corporation Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
WO1997022619A2 (en) * 1995-12-20 1997-06-26 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
WO1998008818A1 (en) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO1998022430A1 (en) * 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING b-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
WO1999043672A1 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase a2
WO2000005223A2 (en) * 1998-07-23 2000-02-03 Astrazeneca Ab Heterocyclic derivatives and their use as integrin inhibitors
WO2000018770A1 (en) * 1998-09-30 2000-04-06 Glaxo Group Limited Pyrrolopyrrolone derivatives as antiviral agents
WO2000040088A1 (en) * 1999-01-07 2000-07-13 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
US6117901A (en) * 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
WO2000066119A1 (en) * 1999-05-05 2000-11-09 Merck & Co., Inc. Novel prolines as antimicrobial agents
EP1086946A1 (en) * 1998-06-08 2001-03-28 Ajinomoto Co., Inc. Benzamidine derivative

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4184658A (en) 1978-02-13 1980-01-22 General Electric Company Cushion mount for prime mover
JPS60181081A (ja) 1984-02-29 1985-09-14 Kaken Pharmaceut Co Ltd 新規ビスベンゾフラニルケトン誘導体
JPH04112868A (ja) 1990-09-03 1992-04-14 Otsuka Pharmaceut Co Ltd 置換ヘテロ環を有するフェニルカルボン酸誘導体
JPH0543574A (ja) 1991-08-13 1993-02-23 Wakamoto Pharmaceut Co Ltd ヘテロ環置換テトラゾール−１−酢酸誘導体
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
PL190866B1 (pl) 1996-07-25 2006-02-28 Biogen Inhibitor adhezji komórek, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
ATE289991T1 (de) 1997-12-23 2005-03-15 Aventis Pharma Ltd Substituierte beta-alaninen
TR200100190T2 (tr) * 1998-05-28 2001-05-21 Biogen, Inc. Yeni VLA4 inhibitörü: oMePUPA-V.
ID27414A (id) 1998-06-30 2001-04-05 Pfizer Produsts Inc Penghambat-penghambat non-peptidil dari pengikat sel tergantung vla-4 yang bermanfaat dalam pengobatan penyakit-penyakit inflamasi, autoimun dan pernafasan
GB9916374D0 (en) 1998-07-23 1999-09-15 Zeneca Ltd Chemical compounds
US6608084B1 (en) 1998-08-26 2003-08-19 Aventis Pharma Ltd. Aza-bicycles which modulate the inhibition of cell adhesion
EP1153017B1 (en) 1999-02-16 2006-05-03 Aventis Pharma Limited Bicyclic compounds and their use as integrin receptor ligands
JP2000344666A (ja) 1999-04-01 2000-12-12 Sankyo Co Ltd 糖及び脂質代謝改善剤
BR0010599A (pt) 1999-04-12 2002-02-13 Aventis Pharma Ltd Compostos de heteroarila bicìclicos substituìdos como antagonistas de integrina
ATE421958T1 (de) 1999-05-05 2009-02-15 Aventis Pharma Ltd Substituierte bizyclische verbindungen
ATE281433T1 (de) 1999-05-05 2004-11-15 Aventis Pharma Ltd Substituierte pyrrolidine als inhibitoren der zelladhäsion
DE60009480T2 (de) 1999-05-05 2005-09-01 Aventis Pharma Ltd., West Malling Harnstoffe als modulatoren der zelladhäsion
US6756378B2 (en) * 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
IL146288A0 (en) 1999-06-30 2002-07-25 Daiichi Seiyaku Co Vla-4 inhibitor compounds
JP2003506491A (ja) 1999-08-13 2003-02-18 バイオジェン インコーポレイテッド 細胞接着インヒビター
AU2155001A (en) 1999-11-10 2001-06-06 Aventis Pharma Deutschland Gmbh N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa
EE200200372A (et) * 1999-12-28 2003-12-15 Pfizer Products Inc. VLA-4 sõltuva raku seostumise mittepeptiidsed inhibiitorid, mis on kasutatavad põletiku-, autoimmuun- ja respiratoorsete haiguste raviks
GB0001346D0 (en) 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
GB0004686D0 (en) 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
AU2001235806A1 (en) 2000-03-01 2001-09-12 Aventis Pharma Limited 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
KR100568841B1 (ko) 2000-07-19 2006-04-10 에프. 호프만-라 로슈 아게 엔도텔린-전환 효소의 억제제로서의 피롤리딘 유도체
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221815A (en) * 1975-01-03 1980-09-09 Hoechst Aktiengesellschaft Benzoic acids, their derivatives and process for preparing them
DE2500157C2 (de) * 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
US4181658A (en) * 1977-02-18 1980-01-01 Hoechst Aktiengesellschaft Certain nicotinamido-n-benzoic acid derivatives
EP0023569A1 (de) * 1979-07-13 1981-02-11 Dr. Karl Thomae GmbH Carbonsäure-Derivate, deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0585155A1 (fr) * 1992-07-28 1994-03-02 Adir Et Compagnie Peptides dérivés de trifluorométhylcétones ayant une actovoté inhibants d'élastase leucocytaire humaine (HLE), leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO1995030673A1 (en) * 1994-05-05 1995-11-16 British Technology Group Limited Anti-cancer compounds containing cyclopentaquinazoline ring
WO1996004267A1 (en) * 1994-08-01 1996-02-15 Laboratorios Menarini S.A. Naphthalene amides having leukotriene-antagonistic action
WO1997002024A1 (en) * 1995-06-30 1997-01-23 Smithkline Beecham Corporation Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
WO1997022619A2 (en) * 1995-12-20 1997-06-26 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
WO1998008818A1 (en) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO1998022430A1 (en) * 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING b-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
US6117901A (en) * 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
WO1999043672A1 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase a2
EP1086946A1 (en) * 1998-06-08 2001-03-28 Ajinomoto Co., Inc. Benzamidine derivative
WO2000005223A2 (en) * 1998-07-23 2000-02-03 Astrazeneca Ab Heterocyclic derivatives and their use as integrin inhibitors
WO2000018770A1 (en) * 1998-09-30 2000-04-06 Glaxo Group Limited Pyrrolopyrrolone derivatives as antiviral agents
WO2000040088A1 (en) * 1999-01-07 2000-07-13 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
WO2000066119A1 (en) * 1999-05-05 2000-11-09 Merck & Co., Inc. Novel prolines as antimicrobial agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Derivation of Pharmacophore and CoMFA ModelsforLeukotriene D4 ReceptorAntagonists of theQuinolinyl(bridged)aryl Series. Albert P.et al.J.Med.Chem.,Vol.43 No.3. 2000 *

Also Published As

Publication number Publication date
MXPA03005838A (es) 2003-09-10
KR20030067730A (ko) 2003-08-14
CA2430978A1 (en) 2002-07-11
AR035218A1 (es) 2004-05-05
TWI312779B (enExample) 2009-08-01
JP4212358B2 (ja) 2009-01-21
WO2002053534A1 (en) 2002-07-11
EP1346982A4 (en) 2005-08-10
BR0116608A (pt) 2004-06-29
EP1346982B1 (en) 2011-09-14
EP1346982A1 (en) 2003-09-24
US20040110945A1 (en) 2004-06-10
RU2003123115A (ru) 2005-03-27
IL156064A0 (en) 2003-12-23
CN1483024A (zh) 2004-03-17
AU2002219555B2 (en) 2006-11-30
WO2002053534A8 (en) 2002-09-19
NO20032994L (no) 2003-08-27
HK1060726A1 (zh) 2004-08-20
RU2290403C2 (ru) 2006-12-27
NO326014B1 (no) 2008-09-01
CA2430978C (en) 2012-05-15
JPWO2002053534A1 (ja) 2004-04-30
ATE524441T1 (de) 2011-09-15
NO20032994D0 (no) 2003-06-27
HK1081545A1 (zh) 2006-05-19
KR100884877B1 (ko) 2009-02-23
US7157487B2 (en) 2007-01-02

Similar Documents

Publication Publication Date Title
CN100471838C (zh) Vla-4抑制剂
CN112218859B (zh) 蛋白水解调节剂及相关使用方法
CN113164775B (zh) 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
CN1974596B (zh) 丙型肝炎病毒抑制剂
JP2020528918A (ja) アンドロゲン受容体の標的化分解のための化合物および方法
WO2013174937A1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
EP3538528A1 (en) Pyrrole amides as alpha v integrin inhibitors
JP2022521453A (ja) 複素環式の誘導体
SG191291A1 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
CN107001342A (zh) 新化合物
EP1819332B1 (en) Pyrrolopyridine-2-carboxylic acid amides
EP1757602A1 (en) Vla-4 inhibitor
CN100396680C (zh) 极迟抗原-4抑制剂
JPH07330695A (ja) 新規カルボン酸誘導体またはその塩、およびその医薬用途
HK1060726B (zh) Vla-4抑制剂
HK1081545B (en) Vla-4 inhibitors
HK40035615A (en) Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
KR20020095418A (ko) Ｖｌａ-4 억제제 화합물
WO1999020632A1 (en) Fused imidazopyridine derivatives, process for producing the same, and preparations containing the same
HK1210147B (en) Pyridine-2-amides useful as cb2 agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1060726

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1060726

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090325

Termination date: 20141228

EXPY Termination of patent right or utility model